The hospital chain reported strong growth driven by its Gurugram facility, international patient inflow, and operational efficiencies
Diagnostic major processes 59 million tests in Q4FY26 as revenue rises 20% and specialty testing portfolio expands
Former DCGI and now advisor to UP CM highlights medical device growth, healthcare expansion, and investment opportunities in the state
Successful inspection outcome strengthens company’s regulatory compliance and manufacturing standards in China
Designed for high-throughput genomic analysis, the laboratory enables accurate, consistent, and scalable testing, delivering high standards of reporting excellence
The US FDA completed a pre-license inspection of Biocon Biologics’ biosimilars manufacturing site at Biocon Park between April 20 and April 29, 2026
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Workshop focused on strengthening sterile processing standards, infection prevention, and CSSD best practices in healthcare settings
Notice of Compliance from Health Canada enables marketing authorisation for cancer biosimilar in Canadian market
Approval for generic Ozempic® in Canada strengthens OneSource’s global CDMO footprint in complex peptide injectable manufacturing
Subscribe To Our Newsletter & Stay Updated
